Press releases

New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease

July 14, 2020 - Other press release

Stockholm, July 14, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer’s Clinical Trials Consortium ...

Interim Report for the period January – June 2020

July 10, 2020 - Regulatory press release

Continued performance according to plan Key events during the second quarter 2020 BioArctic communicated that the mechanism of action for the AD1801 antibody project is ...

Invitation to presentation of BioArctic’s Interim Report for the period January – June 2020 on July 10 at 9.30 a.m. CET

July 1, 2020 - Regulatory press release

Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June ...

BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease

June 29, 2020 - Other press release

Stockholm, Sweden, June 29, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they ...

Members of BioArctic’s Board of Directors and management increase their shareholdings

May 26, 2020 - Regulatory press release

Stockholm, Sweden, May 26, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have ...

Report from Annual General Meeting in BioArctic (publ)

May 7, 2020 - Regulatory press release

Stockholm, Sweden, May 7, 2020 - BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting.  The following resolutions were adopted. Adoption ...

Interim Report for the period January – March 2020

April 22, 2020 - Regulatory press release

Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy disruptions to its operations ...

Invitation to presentation of BioArctic’s Interim Report for the first quarter 2020 on April 22 at 9.30 a.m. CET

April 15, 2020 - Regulatory press release

Stockholm, Sweden, April 15, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2020 ...

Notice of Annual General Meeting in BioArctic AB (Publ)

April 7, 2020 - Regulatory press release

The Board of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held on Thursday, 7 May 2020 More information about ...

BioArctic publishes the Annual Report for 2019

April 2, 2020 - Regulatory press release

Stockholm April 2, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) hereby announces that the Annual Report for the 2019 has been published in ...

The Nomination Committee’s proposal for the election of board members in BioArctic AB

March 24, 2020 - Regulatory press release

Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for ...

Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401

March 3, 2020 - Other press release

Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the ...

Full Year Report for the period January – December 2019

February 6, 2020 - Regulatory press release

Enhanced project portfolio from a successful year

Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET

January 28, 2020 - Other press release

Stockholm, Sweden, January 28, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Full Year Report for the period January – December ...